生物制药：临床试验管线追踪-Biopharma_ Clinical Trial Pipeline Tracker

Summary of Clinical Trial Pipeline Tracker Industry Overview - Industry: Biopharma - Region: North America - Industry View: In-Line for Major Pharmaceuticals, Attractive for Biotechnology [7][7] Key Changes in Clinical Trials New Trials - Alector: Initiated a Phase 2 trial (NCT07105709) for an Open-label Extension Study in Participants With Early Alzheimer's Disease [9] - BioNTech: Advancing BNT327 (PD-L1xVEGF bispecific) combinations, including a new Phase 1/2 trial in combination with BNT326 (HER3 ADC) in NSCLC (NCT07111520) and a Phase 1/2 trial of BNT327 with BNT314 and chemotherapy in advanced CRC (NCT07079631) [9][9] - Bristol-Myers Squibb: Initiated a Phase 2/3 trial (NCT07106762) of Izalontamab Brengitecan (EGFRxHER3 bispec) vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer [9] - Gilead Sciences: Initiated a Phase 1 trial (NCT07115368) of GS-1219 in people with HIV, indicating progress in its next-gen HIV pipeline [9] - Neurocrine: Initiated a Phase 3 trial (NCT07114874) for Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia [9] Withdrawn Trials - Sarepta: The Phase 3 trial (NCT06952686) of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants was withdrawn [4][24] Recruitment Updates - BioNTech: Currently recruiting for a Phase 1/2 study (NCT07079631) to test the combination of BNT314 and BNT327 with chemotherapy in advanced colorectal cancer [10] - Merck: Recruiting in a Phase 3 study (NCT07044297) to prevent HIV-1 [11] Completed Trials - Amgen: Completed recruitment for a Phase 3 trial (NCT06104124) evaluating Dazodalibep in participants with Sjögren's Syndrome [17] - Ionis: Completed recruitment for a Phase 3 trial (NCT04768972) in Amyotrophic Lateral Sclerosis participants [17] Other Important Information - The report includes a comprehensive list of clinical trials, their stages, and statuses, providing insights into the ongoing research and development efforts within the biopharma sector [2][7][21] - The document emphasizes the potential conflicts of interest due to Morgan Stanley's business relationships with the companies covered in the research [7] This summary encapsulates the critical updates and insights from the clinical trial pipeline tracker, highlighting the dynamic nature of the biopharma industry in North America.